A high-content cytokine screen identifies myostatin propeptide as a positive regulator of primitive chronic myeloid leukemia cells.
Aberrantly expressed cytokines in the bone marrow niche are increasingly recognized as critical mediators of survival and expansion of leukemic stem cells. To identify regulators of primitive chronic myeloid leukemia cells, we performed a high-content cytokine screen using primary CD34+ CD38low chronic phase choric myeloid leukemia cells. Out of the 313 unique human cytokines evaluated, 11 were found to expand cell numbers ≥ 2-fold in a 7-day culture. Focusing on novel positive regulators of primitive chronic myeloid leukemia cells, the myostatin antagonist myostatin propeptide gave the largest increase in cell expansion and was chosen for further studies. Herein, we demonstrate that myostatin propeptide expands primitive chronic myeloid leukemia and normal bone marrow cells, as shown by increased colony-forming capacity. For primary chronic myeloid leukemia samples, retention of CD34-expression was also seen after culture. Furthermore, we show expression of MSTN by chronic myeloid leukemia mesenchymal stromal cells, and that myostatin propeptide has a direct and instant effect on chronic myeloid leukemia cells, independent of myostatin, by demonstrating binding of myostatin propeptide to the cell surface and increased phosphorylation of STAT5 and SMAD2/3. In summary, we identify myostatin propeptide as a novel positive regulator of primitive chronic myeloid leukemia cells and corresponding normal hematopoietic cells.